These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21697892)

  • 1. Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study.
    Di Zenzo G; Thoma-Uszynski S; Calabresi V; Fontao L; Hofmann SC; Lacour JP; Sera F; Bruckner-Tuderman L; Zambruno G; Borradori L; Hertl M
    J Invest Dermatol; 2011 Nov; 131(11):2271-80. PubMed ID: 21697892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230.
    Thoma-Uszynski S; Uter W; Schwietzke S; Schuler G; Borradori L; Hertl M
    J Immunol; 2006 Feb; 176(3):2015-23. PubMed ID: 16424234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
    Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
    J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses.
    Feliciani C; Caldarola G; Kneisel A; Podstawa E; Pfütze M; Pfützner W; Hertl M
    Br J Dermatol; 2009 Aug; 161(2):306-12. PubMed ID: 19485996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid.
    Di Zenzo G; Thoma-Uszynski S; Fontao L; Calabresi V; Hofmann SC; Hellmark T; Sebbag N; Pedicelli C; Sera F; Lacour JP; Wieslander J; Bruckner-Tuderman L; Borradori L; Zambruno G; Hertl M
    Clin Immunol; 2008 Sep; 128(3):415-26. PubMed ID: 18571472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demonstration of epitope spreading in bullous pemphigoid: results of a prospective multicenter study.
    Hashimoto T; Tsuruta D; Dainichi T; Hamada T; Furumura M; Ishii N
    J Invest Dermatol; 2011 Nov; 131(11):2175-7. PubMed ID: 21997418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses.
    Fania L; Caldarola G; Müller R; Brandt O; Pellicano R; Feliciani C; Hertl M
    Clin Immunol; 2012 Jun; 143(3):236-45. PubMed ID: 22534318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the combination of BP180-NC16a enzyme-linked immunosorbent assay and BP230 enzyme-linked immunosorbent assay in the diagnosis of bullous pemphigoid.
    Yang B; Wang C; Chen S; Chen X; Lu X; Tian H; Yu M; Zhang D; Shi Z; Zhou G; Zhang F
    Indian J Dermatol Venereol Leprol; 2012; 78(6):722-7. PubMed ID: 23075641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study.
    Fichel F; Barbe C; Joly P; Bedane C; Vabres P; Truchetet F; Aubin F; Michel C; Jegou J; Grange F; Antonicelli F; Bernard P
    JAMA Dermatol; 2014 Jan; 150(1):25-33. PubMed ID: 24226428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgG antibodies against immunodominant C-terminal epitopes of BP230 do not induce skin blistering in mice.
    Feldrihan V; Licarete E; Florea F; Cristea V; Popescu O; Sitaru C; Chiriac MT
    Hum Immunol; 2014 Apr; 75(4):354-63. PubMed ID: 24468586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and immunological profiles of anti-BP230-type bullous pemphigoid: Restriction of epitopes to the C-terminal domain of BP230, shown by novel ELISAs of BP230-domain specific recombinant proteins.
    Hayakawa T; Teye K; Hachiya T; Uehara R; Hashiguchi M; Kawakami T; Li X; Tsuchisaka A; Ohara K; Sogame R; Koga H; Hamada T; Ohata C; Furumura M; Ishii N; Fukano H; Shimozato K; Hashimoto T
    Eur J Dermatol; 2016 Apr; 26(2):155-63. PubMed ID: 27087683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230.
    Skaria M; Jaunin F; Hunziker T; Riou S; Schumann H; Bruckner-Tuderman L; Hertl M; Bernard P; Saurat JH; Favre B; Borradori L
    J Invest Dermatol; 2000 May; 114(5):998-1004. PubMed ID: 10771483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity.
    Oyama N; Setterfield JF; Powell AM; Sakuma-Oyama Y; Albert S; Bhogal BS; Vaughan RW; Kaneko F; Challacombe SJ; Black MM
    Br J Dermatol; 2006 Jan; 154(1):90-8. PubMed ID: 16403100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid.
    Hashimoto T; Ohzono A; Teye K; Numata S; Hiroyasu S; Tsuruta D; Hachiya T; Kuroda K; Hashiguchi M; Kawakami T; Ishii N
    Br J Dermatol; 2017 Jul; 177(1):141-151. PubMed ID: 27716903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgA autoantibodies in the pemphigoids and linear IgA bullous dermatosis.
    Horváth B; Niedermeier A; Podstawa E; Müller R; Hunzelmann N; Kárpáti S; Hertl M
    Exp Dermatol; 2010 Jul; 19(7):648-53. PubMed ID: 20500772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.
    Döpp R; Schmidt E; Chimanovitch I; Leverkus M; Bröcker EB; Zillikens D
    J Am Acad Dermatol; 2000 Apr; 42(4):577-83. PubMed ID: 10727301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180.
    Schmidt E; Skrobek C; Kromminga A; Hashimoto T; Messer G; Bröcker EB; Yancey KB; Zillikens D
    Br J Dermatol; 2001 Nov; 145(5):778-83. PubMed ID: 11736901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid.
    Zheng M; Ujiie H; Iwata H; Muramatsu K; Yoshimoto N; Ito T; Ujiie I; Shimizu S; Sato-Matsumura KC; Shimizu H
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):595-600. PubMed ID: 30394605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgE autoantibodies against the intracellular domain of BP180.
    Dresow SK; Sitaru C; Recke A; Oostingh GJ; Zillikens D; Gibbs BF
    Br J Dermatol; 2009 Feb; 160(2):429-32. PubMed ID: 18808416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients.
    Mariotti F; Grosso F; Terracina M; Ruffelli M; Cordiali-Fei P; Sera F; Zambruno G; Mastrogiacomo A; Di Zenzo G
    Br J Dermatol; 2004 Nov; 151(5):1004-10. PubMed ID: 15541078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.